Lim Phei Ching, Tan Hooi Hoon, Mohd Noor Nurul Ain, Chang Chee Tao, Wong Te Ying, Tan Ee Linn, Ong Chiou Ting, Nagapa Kalyhani, Tai Lee Shyong, Chan Wei Ping, Sin Yong Boey, Tan Yin Shan, Velaiutham Shanty, Mohd Hanafiah Rohaizan
Pharmacy Department, Hospital Pulau Pinang, Ministry of Health Malaysia, George Town, Malaysia.
School of Pharmaceutical Sciences, University Science Malaysia, Gelugor, Malaysia.
J Pharm Policy Pract. 2023 Jul 5;16(1):83. doi: 10.1186/s40545-023-00583-8.
Pharmacist's involvement in optimizing medication adherence among diabetic patients has been implemented for over a decade. Diabetes Medication Therapy Adherence Clinic (DMTAC) was set up to educate diabetic patients, monitor treatment outcomes, and manage drug-related problems. While evidence shows that pharmacist-led DMTAC was effective in reducing HbA1c, there was limited data regarding the impact of different intervention types and default to follow-up on glycemic control.
To assess the impact DMTAC on glycemic control and the difference in glycemic control between hospital and health clinic settings as well as defaulter and non-defaulter. In addition, the impact of pharmacist's interventions, DMTAC follow-up frequencies, and duration of diabetes on glycemic control were also determined.
A retrospective study was conducted among diabetes patients under DMTAC care between January 2019 and June 2020 in five hospitals and 23 primary health clinics. Patients' demographics data, treatment regimens, frequencies of DMTAC visits, defaulter (absent from DMTAC visits) and types of pharmacists' intervention were retrieved from patients' medical records and electronic database. HbA1c was collected at baseline, 4-6 months (post-1), and 8-12 months (post-2).
We included 956 patients, of which 60% were females with a median age of 58.0 (IQR: 5.0) years. Overall, the HbA1c reduced significantly from baseline (median: 10.2, IQR: 3.0) to post-1 (median: 8.8, IQR: 2.7) and post-2 (median: 8.3, IQR: 2.6%) (p < 0.001). There were 4317 pharmacists' interventions performed, with the majority being dosage adjustment (n = 2407, 55.8%), followed by lab investigations (849, 19.7%), drugs addition (653, 15.1%), drugs discontinuation (408, 9.5%). Patients treated in hospitals received significantly more interventions than those treated in primary health clinics (p < 0.001). We observed significantly less reduction in HbA1c in DMTAC follow-up defaulters than non-defaulters after 1 year (- 1.02% vs. - 2.14%, p = 0.001). Frequencies of DMTAC visits (b: 0.19, CI: 0.079-0.302, p = 0.001), number of dosage adjustments (b: 0.83, CI: 0.015-0.151, p = 0.018) and number of additional drugs recommended (b: 0.37, CI: 0.049-0.691, p = 0.024) had positive impact on glycemic control whereas duration of diabetes (b: - 0.0302, CI: - 0.0507, - 0.007, p = 0.011) had negative impact.
Glycemic control improved significantly and sustained up to one year among patients in pharmacists-led DMTAC. However, DMTAC defaulters experienced poorer glycemic control. Considering more frequent visits and targeted interventions by pharmacists at DMTAC resulted in improved HbA1c control, these strategies should be taken into account for future program planning.
药剂师参与优化糖尿病患者的药物依从性已实施了十多年。糖尿病药物治疗依从性诊所(DMTAC)的设立是为了教育糖尿病患者、监测治疗结果并管理药物相关问题。虽然有证据表明药剂师主导的DMTAC在降低糖化血红蛋白(HbA1c)方面有效,但关于不同干预类型以及失访对血糖控制影响的数据有限。
评估DMTAC对血糖控制的影响,以及医院和健康诊所环境之间、失访者和未失访者之间血糖控制的差异。此外,还确定了药剂师干预、DMTAC随访频率以及糖尿病病程对血糖控制的影响。
对2019年1月至2020年6月期间在五家医院和23家基层医疗诊所接受DMTAC护理的糖尿病患者进行了一项回顾性研究。从患者的病历和电子数据库中检索患者的人口统计学数据、治疗方案、DMTAC就诊频率、失访者(未参加DMTAC就诊)以及药剂师干预类型。在基线、4 - 6个月(1期后)和8 - 12个月(2期后)收集HbA1c数据。
我们纳入了956名患者,其中60%为女性,中位年龄为58.0(四分位间距:5.0)岁。总体而言,HbA1c从基线(中位值:10.2,四分位间距:3.0)显著降低至1期后(中位值:8.8,四分位间距:2.7)和2期后(中位值:8.3,四分位间距:2.6%)(p < 0.001)。共进行了4317次药剂师干预,其中大多数是剂量调整(n = 2407,55.8%),其次是实验室检查(849,19.7%)、加药(653,15.1%)以及停药(408,9.5%)。在医院接受治疗的患者比在基层医疗诊所接受治疗的患者接受的干预显著更多(p < 0.001)。我们观察到,1年后DMTAC随访失访者的HbA1c降低幅度明显低于未失访者(-1.02%对-2.14%,p = 0.001)。DMTAC就诊频率(b:0.19,置信区间:0.079 - 0.302,p = 0.001)、剂量调整次数(b:0.83,置信区间:0.015 - 0.151,p = 0.018)以及推荐加用药物的数量(b:0.37,置信区间:0.049 - 0.691,p = 0.024)对血糖控制有积极影响,而糖尿病病程(b:-0.0302,置信区间:-0.0507,-0.007,p = 0.011)有负面影响。
在药剂师主导的DMTAC中,患者的血糖控制显著改善并持续了一年。然而,DMTAC失访者的血糖控制较差。鉴于在DMTAC中更频繁的就诊和药剂师的针对性干预可改善HbA1c控制,在未来的项目规划中应考虑这些策略。